Cipla Ltd

💨 Cipla Secures FDA Approval for First AB-Rated Generic Albuterol Inhaler

• FDA approves Cipla's Abbreviated New Drug Application for Albuterol Sulfate Inhalation Aerosol (90 mcg)

• First AB-rated generic therapeutic equivalent to GlaxoSmithKline's Ventolin® HFA

• Indicated for bronchospasm treatment/prevention in patients aged 4+ with reversible obstructive airway disease

• Targets $1.5 billion U.S. albuterol market (IQVIA data)

• Manufacturing at new Cipla facility in Fall River, Massachusetts

• Expected U.S. launch in first half of fiscal year 2026-27

• Strengthens Cipla's U.S. respiratory portfolio